MarketInOut Stock Screener Log In | Sign Up

MaxCyte Inc

NASDAQ • Healthcare • Medical Devices • Quote as of 10/30/2026
MaxCyte Inc stock price and volume chart

Company Profile

IndustryMedical Devices
SectorHealthcare
ExchangeNASDAQ
Market Capitalization164.1 mln
Float94.82 mln
Earnings Date11/10/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-3.11
Reliable

Relative Strength

97 / 100
Top performer

Debt / Equity

0.11
Very low leverage

Pre-Tax Margin

-115%
Severely loss-making

ROE

-20.50
Deeply negative

Business Description

MaxCyte is a Rockville, Maryland-based life sciences company that develops and sells advanced cell engineering technology used in drug discovery, biomanufacturing, and the development of cell-based therapies. Its core platform centers on electroporation instruments that allow researchers and manufacturers to introduce genetic material into cells at various scales, from small laboratory work to large commercial production. The company generates revenue by licensing its technology and selling both its instruments and the single-use components that support them to pharmaceutical, biotechnology, and cell therapy companies worldwide.

Key Fundamentals

EPS-0.32
ROE-20.50
RPS0.29
ROIC-37.38
ROA-17.56
EBITDA, mln-30.59
EV / EBITDA-2.33
EV / EBIT-2.00
Revenue, mln31.05
EV / Revenue2.30

Quote Details

Last 1.59
Change -0.14 (-8.09%)
Open 1.71
Volume 962,127
Turnover 1,529,782
Average Volume 1,508,769

Financial Ratios

Pre-Tax Profit Margin-115
Leverage Ratio1.16
Current Ratio12.26
Price / Book1.03
Price / Tangible Book1.03
Debt / Equity0.11
Price / Sales5.31

Financial Strength

Altman Z-Score1.85
Piotroski F-Score 2 / 9
Beneish M-Score-3.11
Short Ratio1.81
Short % of Float1.79

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 13.57% 96 / 100   
1 Month 45.87% 99 / 100   
2 Months 55.88% 98 / 100   
6 Months 80.68% 98 / 100   
1 Year 5.3% 59 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog